Promising combo targets tough blood cancer before transplant
NCT ID NCT04566887
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests whether adding the targeted drug acalabrutinib to standard R-CHOP chemotherapy improves outcomes for people with untreated mantle cell lymphoma. About 105 participants will receive the combination, then some will proceed to stem cell transplant. The study measures how many achieve complete remission and how long the disease stays controlled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
acalabrutinib (a targeted cancer drug) combined with R-CHOP chemotherapy
What this could lead to
If successful, this combination could become a new standard first treatment for mantle cell lymphoma, potentially improving remission rates and long-term control.
What could go wrong
This is an early-phase, non-randomized trial with only 105 participants. Results may not apply to all patients, and side effects from the drug combination could be significant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
BC Cancer Agency
Vancouver, British Columbia, V5Z 4E6, Canada
-
Centre Hospitalier Universitaire de Québec
Québec, Quebec, G1J 1Z4, Canada
-
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
-
QEII Health Sciences Centre
Halifax, Nova Scotia, B3H 2Y9, Canada
-
Sunnybrook Research Institute
Toronto, Ontario, Canada